Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report

Pseudoprogression has been deemed as a rare clinical phenomenon during the treatment of immune checkpoint inhibitors in patients with advanced cancers, especially in periampullary carcinoma, however, leaving potential molecular mechanism remain unknown. PATIENT CONCERNS: Regular examination after ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junhui, Wang, Yan, Che, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875975/
https://www.ncbi.nlm.nih.gov/pubmed/36705379
http://dx.doi.org/10.1097/MD.0000000000032644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875975/
https://www.ncbi.nlm.nih.gov/pubmed/36705379
http://dx.doi.org/10.1097/MD.0000000000032644

Ejemplares similares